Senores Pharma.Q1 FY27
Senores Pharma. Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,480P/E: 55.1Market Cap: ₹7.0K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 1
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 1- →Target revenue of INR 2,500 to 3,000 crores within 3-4 years.
- →FY '27 guidance: 30%-40% revenue growth; 50%-60% PAT growth.
- →Similar growth trajectory expected post FY '27, though exact FY '28 guidance is premature.
- →Growth driven by:
- → - Regulated markets: US ANDA portfolio expanding from 30 to 58 approved ANDAs; 23 commercialized; 35 more to launch in 18-20 months.
- → - Emerging markets: 500+ current product approvals; 900+ registrations in pipeline.
- → - India branded generics: expected to reach INR 50-60 crores sales with 35%-40% EBITDA.
- →Production capacity expansion at Apnar and US facilities to support growth.
- →Strong pipeline with 39 molecules under development, providing multiyear growth visibility.
- →Growth drivers balanced between regulated (~70%) and emerging (~30%) markets, expected to maintain this mix.
Margin guidance
Category 3- →Senores Pharmaceuticals guides for a **50% PAT growth in FY27**, with expectations for growth to continue thereafter, though exact FY28 numbers are premature to specify.
- →The company targets reaching **INR 2,500 crores revenue mark in 3-4 years**, with sustained minimum margins around **30%**.
- →Revenue growth guidance for FY27 is around **30%-40%**, supported by a strong pipeline of approved and upcoming ANDAs, and expanding regulated and emerging markets.
- →EBITDA margins improved to around **30%**, with emerging markets EBITDA margin expected to be around **18%-20% for the full year**.
- →Capex planned at **INR 100-120 crores** in FY27 mainly for capacity expansion.
- →Growth drivers include regulated markets (US, Canada, UK, etc.), emerging markets, and branded generics in India.
- →The company plans steady launches, capacity expansion, and sustained operational efficiency to support growth.
3 more insights locked — sign up free to unlock
Fundraise plans
- →No specific mention of any current or future fundraising through debt or equity is made in the provided transcript from the Senores Pharmaceuticals Limited earnings call.
- →The discussion primarily focuses on operational growth, capacity expansion, and strategic utilization of existing IPO proceeds, including INR100-120 crores of planned capex in FY27.
- →The company has scaled down its sterile injectable project, reallocating funds towards oral solid capacity expansions in the US and India.
- →Any major changes in the use of IPO proceeds, including a smaller pilot project for sterile injectables, require shareholder approval.
- →No direct commentary on raising new equity or debt financing was provided in the discussed Q&A or management commentary.
Order book
Yes- →Senores Pharmaceuticals has about 58 approved ANDAs, with 35 approved but yet to be launched.
- →There are 39 more ANDAs (molecules) under development, some filed, some to be filed.
- →The emerging markets segment has around 500 approved product registrations.
- →Additionally, about 900 product registrations are currently in the pipeline, already filed with respective Ministries of Health.
- →This robust pipeline forms a strong orderbook, supporting continued growth in both regulated and emerging markets.
- →The company aims to leverage this portfolio for sustained revenue growth reaching INR2,500 to INR3,000 crores in 3-4 years.
Capex plans
Yes- →FY27 Capex planned: INR 100-120 crores across subsidiaries, mainly for capacity expansion in oral solids and starting an injectable pilot plant.
- →Apnar facility: Expanding with third and fourth production lines to ramp up oral solid manufacturing capacity.
- →US plant capacities are also being increased to support regulated market growth.
- →Sterile injectable project: Scaled down to a pilot facility with lower cost; full-scale execution pushed to H2 FY27 pending shareholder approval.
- →Zoraya Pharma (US subsidiary, B2C arm) expected to commence operations around September-October 2026.
- →No major new greenfield facilities planned; focus is on optimizing existing facilities for better return on investment.
How does Senores Pharma. rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Senores Pharma.
Rev 1Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Senores Pharma. rank in Pharmaceuticals & Biotechnology?
Compare Senores Pharma. against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.